Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

To improve the outcomes of patients with the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patien...

Full description

Bibliographic Details
Main Authors: Paul G. Richardson, Brian G. Durie, Laura Rosiñol, Maria-Victoria Mateos, Angela Dispenzieri, Philippe Moreau, Shaji Kumar, Noopur Raje, Nikhil Munshi, Jacob P. Laubach, Peter O’Gorman, Elizabeth O’Donnell, Peter Voorhees, Thierry Facon, Joan Bladé, Sagar Lonial, Aurore Perrot, Kenneth C. Anderson
Format: Article
Language:English
Published: Ferrata Storti Foundation 2023-08-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/11221

Internet

https://haematologica.org/article/view/11221

Similar Items